Flightpath Bio Launches via Illumina Accelerator for Largest

BERKELEY, Calif., Feb 09, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).
* Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectrum, targeted therapeutics into the clinic
* Company aims to combine deep genomic sequencing, metabolomics and immune-cell profiling with next generation machine-learning approaches to solve multiple pathogen-driven diseases and syndromes

Related Keywords

Berkeley , California , United States , Matt Tindall , Michael Bellas , Twitter , Flightpath Biosciences Inc , Flightpath Biosciences , Illumina Accelerator , Persistent Lyme Disease , Flightpath Co Founder , Persistent Lyme , Mark De Souza , பெர்க்லி , கலிஃபோர்னியா , ஒன்றுபட்டது மாநிலங்களில் , மேட் டிண்டால் , மைக்கேல் பெல்லாஸ் , ட்விட்டர் , இல்லுமின முடுக்குப்பொறி , தொடர்ந்து லைம் நோய் , தொடர்ந்து லைம் , குறி டி ஸூஸ ,